Topical retapamulin in the management of infected traumatic skin lesions

Therapeutics and Clinical Risk Management

Volumn 5, Issue 1, 2009, Pages 41-49

  Shawar, Ribhi ^a   Scangarella Oman, Nicole ^a   Dalessandro, MaryBeth ^a   Breton, John ^a   Twynholm, Monique ^b   Li, Gang ^a   Garges, Harmony ^a  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Retapamulin; Skin infections; Staphylococcus aureus; Topical antibiotic; Traumatic skin lesions

Indexed keywords

CEFALEXIN; ERYTHROMYCIN; FUSIDIC ACID; MACROLIDE; METICILLIN; OXACILLIN; PLACEBO; PSEUDOMONIC ACID; RETAPAMULIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; APPLICATION SITE IRRITATION; CLINICAL TRIAL; COAGULASE NEGATIVE STAPHYLOCOCCUS; DERMATITIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG POTENCY; DRUG SAFETY; HUMAN; IMPETIGO; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OINTMENT; PATIENT COMPLIANCE; REVIEW; SKIN INFECTION; SKIN INJURY; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES; UNSPECIFIED SIDE EFFECT; WOUND INFECTION;

EID: 77949437391     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005;41:1373-1406.
2. Bowler PG, Duerden BI, Armstrong DG. Wound microbiology and associated approaches to wound management. Clin Microbiol Rev. 2001;14:244-269.
3. Perera G, Hay R. A guide to antibiotic resistance in bacterial skin infections. J Eur Acad Dermatol Venereol. 2005;19:531-545.
4. Patel M, Waites KB, Hoesley CJ, Stamm AM, Canupp KC, Moser, SA. Emergence of USA300 MRSA in a tertiary medical centre: implications for epidemiological studies. J Hosp Infect. 2008;68:208-213.
5. Gupta K, Macintyre A, Vanasse G, Dembry LM. Trends in prescribing beta-lactam antibiotics for treatment of community-associated methicillin-resistant Staphylococcus aureus infections. J Clin Microbiol. 2007;45:3930-3934.
6. Jacobs MR, Jones RN, Giordano PA. Oral beta-lactams applied to uncomplicated infections of skin and skin structures. Diagn Microbiol Infect Dis. 2007;57:55S-65S.
7. Deshpande LM, Fix AM, Pfaller MA, Jones RM. Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): correlations of results from disk diffusion, Etest and reference dilution methods. Diagn Microbiol Infect Dis. 2002;42:283-290.
8. Upton A, Lang S, Heffernan H. Mupirocin and Staphylococcus aureus: a recent paradigm of emerging antibiotic resistance. J Antimicrob Chemother. 2003;51:613-617.
9. Appelbaum PC. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2006;12(Suppl 1):16-23.
10. Walker ES, Vasquez JE, Dula R, Bullock H, Sarubbi SA. Mupirocin-resistant, methicillin-resistant Staphylococcus aureus: does mupirocin remain effective? Infect Control Hosp Epidemiol. 2003;24:342-346.
11. Koning S, Verhagen AP, van Suijlekom-Smit LW, Morris A, Butler CC, van der Wouden JC. Interventions for impetigo. Cochrane Database Syst Rev. 2003:CD003261.
12. Gisby J, Bryant J. Efficacy of a new cream formulation of mupirocin: comparison with oral and topical agents in experimental skin infections. Antimicrob Agents Chemother. 2000;44:255-260.
13. Bikowski J. Secondarily infected wounds and dermatoses: a diagnosis and treatment guide. J Emerg Med. 1999;17:197-206.
14. Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrell KL, Fernandez HA. Comparative in vitro activities of retapamulin (SB-275833) against 141 clinical isolates of Propionibacterium spp., including 117 P. acnes isolates. Antimicrob Agents Chemother. 2006;50:379-381.
15. Pankuch GA, Lin G, Hoellman DB, Good CE, Jacobs MR, Appelbaum PC. Activity of retapamulin against Streptococcus pyogenes and Staphylococcus aureus evaluated by agar dilution, microdilution, E-test, and disk diffusion methodologies. Antimicrob Agents Chemother. 2006;50:1727-1730.
16. Rittenhouse S, Biswas S, Broskey J, et al. Selection of retapamulin, a novel pleuromutilin for topical use. Antimicrob Agents Chemother. 2006;50:3882-3885.
17. Odou MF, Muller C, Calvet L. In vitro activity against anaerobes of retapamulin, a new topical antibiotic for treatment of skin infections. J Antimicrob Chemother. 2007;59:646-651.
18. Pringle M, Poehlsgaard J, Vester B, Long KS. Mutations in ribosomal protein L3 and 23S ribosomal RNA at the peptidyl transferase centre are associated with reduced susceptibility to tiamulin in Brachyspira spp. isolates. Mol Microbiol. 2004;54:1295-1306.
19. Kosowska-Shick K, Clark C, Credito K, et al. Single- and multistep resistance selection studies on the activity of retapamulin compared to other agents against Staphylococcus aureus and Streptococcus pyogenes. Antimicrob Agents Chemother. 2006;50:765-769.
20. Gentry DR, Rittenhouse SF, McCloskey L, Holmes DJ. Stepwise exposure of Staphylococcus aureus to pleuromutilins is associated with stepwise acquisition of mutations in rplC and minimally affects susceptibility to retapamulin. Antimicrob Agents Chemother. 2007;51:2048-2052.
21. Jones RN, Fritsche TR, Sader HS, Ross JE. Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci. Antimicrob Agents Chemother. 2006;50:2583-2586.
22. Williams L, Northwood J, Crowhurst N, Felmingham D. In vitro activity of retapamulin, a novel pleuromutilin, against Staphylococcus spp. (n = 1413) and Streptococcus pyogenes (n = 503) from 26 European centres. In: European Congress of Clinical Microbiology and Infectious Diseases and International Congress of Chemotherapy, 31 March-3 April 2007, Munich, Germany. Poster P790.
23. GlaxoSmithKline. In vitro activity of SB-275833 and comparators against 6,747 hospital- and community-acquired Gram-positive clinical isolates from skin and skin structure infections; data from the retapamulin global surveillance study. Data on file. 2005.
24. Molitoris D, Finegold SM, Bolaños M. In vitro activity of retapamulin and five comparator agents against 226 anaerobic bacterial isolates. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. 6-19 December 2005, Washington, DC, USA. Poster F-2060.
25. Brown SD, Traczewski MM. Retapamulin: in vitro potency, spectrum of activity, MIC and disk breakpoints. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, 16-19 December 2005, Washington, DC, USA. Poster F-2065.
26. Draghi D, Scangarella N, Shawar R, Sahm D. In vitro activity of retapamulin and comparators against 1690 recent Gram-positive clinical isolates. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, 16-19 December 2005, Washington, DC, USA. Poster F-2052.
27. Felmingham D, Williams LJ, Northwood JGE, Crowhurst NA. In vitro activity of retapamulin, a novel pleuromutilin, against Streptococcus pyogenes, Streptococcus agalactiae and 'viridans' streptococci isolates from 26 centers in 14 European countries. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, 16-19 December 2005, Washington, DC, USA. Poster F-2056.
28. Woodford N, Afzal-Shah M, Warner M, Livermore DM. In vitro activity of retapamulin against Staphylococcus aureus isolates resistant to fusidic acid and mupirocin. J Antimicrob Chemother. 2008; Jun 19: Epub ahead of print.
29. Howden BP, Grayson LM. Dumb and dumber - the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus. Clin Infect Dis. 2006;394-400.
30. Free A, Roth E, Dalessandro M, et al. Retapamulin ointment twice daily for 5 days vs oral cephalexin twice daily for 10 days for empiric treatment of secondarily infected traumatic lesions of the skin. Skinmed. 2006;5:224-232.
31. Parish LC, Jorizzo JL, Breton JJ, et al. Topical retapamulin ointment (1%, wt/wt) twice daily for 5 days versus oral cephalexin twice daily for 10 days in the treatment of secondarily infected dermatitis: results of a randomized controlled trial. J Am Acad Dermatol. 2006;55:1003-1013.
32. GlaxoSmithKline. Clinical and microbiological success rates at follow-up. Report number TOCMAA table 17.481. Data on file. 2006.
33. GlaxoSmithKline. Data on file - ABX208-UM2008-00159-00. Collegeville, PA: GlaxoSmithKline; May 2008.
34. Koning S, van der Wouden JC, Chosidow O, et al. Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized double-blind multicentre placebo-controlled trial. Br J Dermatol. 2008;158:1077-1082.
35. Oranje AP, Chosidow O, Sacchidanand S, et al. Topical retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: a randomized, observer-blinded, noninferiority study. Dermatology. 2007;215:331-340.
36. GlaxoSmithKline. Protocol SB-275833/030 - studies 030A and 030B: two identical double-blind, double-dummy, multicenter, comparative phase III studies of the safety and efficacy of topical 1% SB-275833, applied twice daily, versus oral cephalexin, 500 mg in adults, or 12.5 mg/kg (250 mg/5 ml) in children, twice daily, in the treatment of uncomplicated secondarily infected traumatic lesions (study SB-275833/030A). Data on file. 2005.
37. Chosidow O, Oranje AP, Sacchidanand S, et al. Retapamulin as a novel treatment for impetigo: results of a phase III, randomized trial of efficacy and safety versus fusidic acid. Presented at: 15th European Academy of Dermatology and Venereology, 4-8 October 2006, Rhodes, Greece. Poster P041.11.
38. van der Wouden JC, Koning S, Chosidow O, et al. Evaluation of retapamulin, a novel, broad-spectrum, topical antibacterial, for the treatment of impetigo: results of a placebo-controlled, randomized, double-blind, efficacy and safety trial. Presented at: 15th European Academy of Dermatology and Venereology, 4-8 October 2006, Rhodes, Greece. Poster PO41.74.
39. European Medicines Agency. European Public Assessment Report (EPAR) for Altargo (retapamulin). Revision 3. London, UK: European Medicines Agency [updated 2008 May 30; cited 2008 Sep 2]. Available from: http://www.emea.europa. eu/humandocs/Humans/EPAR/altargo/altargo.htm.
40. GlaxoSmithKline. Summary of drug-related adverse events in decreasing frequency. Data on file. 2006.
41. Goldfarb J, Crenshaw D, O'Horo J, Lemon E, Blumer JL. Randomized clinical trial of topical mupirocin versus oral erythromycin for impetigo. Antimicrob Agents Chemother. 1988;32:1780-1783.
42. Perchère JC, Lacey L. Optimizing economic outcomes in antibiotic therapy of patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother. 2000;45:19-24.
43. Brixner DI. Improving acute otitis media outcomes through proper antibiotic use and adherence. Am J Manag Care. 2005;11(Suppl):S202-210.
44. Vrijens B, Urquhart J. Patient adherence to prescribed antimicrobial drug dosing regimens. J Antimicrob Chemother. 2005;55:616-627.
45. Kardas P. Patient compliance with antibiotic treatment for respiratory tract infections. J Antimicrob Chemother. 2002;49:897-903.
46. Kardas P. Comparison of patient compliance with once-daily and twicedaily antibiotic regimens in respiratory tract infections: results of a randomized trial. J Antimicrob Chemother. 2007;59:531-536.
47. Cockburn J, Gibberd RW, Reid AL, Sanson-Fisher RW. Determinants of non-compliance with short term antibiotic regimens. Br Med J. 1987;295:814-818.
48. Pakrooh H. A comparison of sodium fusidate ointment ('Fucidin') alone versus oral antibiotic therapy in soft-tissue infections. Curr Med Res. 1977;5:289-294.
49. Rist T, Parish LC, Capin LR, Sulica V, Bushnell WD, Cupo MA. A comparison of the efficacy and safety of mupirocin cream and cephalexin in the treatment of secondarily infected eczema. Clin Exp Dermatol. 2002;27:14-20.